Literature DB >> 28606760

Progress in the discovery of small molecule modulators of the Cys-loop superfamily receptors.

Brian A Sparling1, Erin F DiMauro2.   

Abstract

The vertebrate Cys-loop family of ligand-gated ion channels (LGICs) are comprised of nicotinic acetylcholine (nAChR), serotonin type 3 (5-HT3R), γ-aminobutyric acid (GABAAR), and glycine (GlyR) receptors. Here, we review efforts to discover selective small molecules targeting one or more Cys-loop receptors, with a focus on state-of-the-art modulators that have been reported over the past five years. Several highlighted compounds offer robust oral bioavailability and central exposure and have thus been useful in delineating pharmacokinetic/pharmacodynamic relationships in pre-clinical disease models. Others offer high levels of subtype and/or inter-superfamily selectivity and have facilitated understanding of complex SAR and pharmacodynamics.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cys-loop receptors; Glycine receptors; Ligand-gated ion channels; Nicotinic acetylcholine receptors; Serotonin type 3 receptors; γ-Aminobutyric acid receptor

Mesh:

Substances:

Year:  2017        PMID: 28606760     DOI: 10.1016/j.bmcl.2017.04.073

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

Review 1.  Glycine receptors and glycine transporters: targets for novel analgesics?

Authors:  Hanns Ulrich Zeilhofer; Mario A Acuña; Jacinthe Gingras; Gonzalo E Yévenes
Journal:  Cell Mol Life Sci       Date:  2017-08-08       Impact factor: 9.261

Review 2.  Recent Insight into Lipid Binding and Lipid Modulation of Pentameric Ligand-Gated Ion Channels.

Authors:  Anna Ananchenko; Toka O K Hussein; Deepansh Mody; Mackenzie J Thompson; John E Baenziger
Journal:  Biomolecules       Date:  2022-06-10

3.  Azologization of serotonin 5-HT3 receptor antagonists.

Authors:  Karin Rustler; Galyna Maleeva; Piotr Bregestovski; Burkhard König
Journal:  Beilstein J Org Chem       Date:  2019-03-25       Impact factor: 2.883

4.  Safety of oral afoxolaner formulated with or without milbemycin oxime in homozygous MDR1-deficient collie dogs.

Authors:  Marlene Drag; Eric Tielemans; Elizabeth Mitchell
Journal:  J Vet Pharmacol Ther       Date:  2022-05-10       Impact factor: 1.567

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.